BioStock: Lipum’s journey told by CSO and Co-founder

Lipum’s drug development is based on the discovery of Bile Salt-Stimulated Lipase and its role in inflammatory processes. The company’s CSO Susanne Lindquist contributed to the discovery during her research at Umeå University, which she tells more about in an interview with BioStock. In addition, we get to know more about Lipum’s journey from its beginnings in 2010 to today, a listed company in clinical phase with the drug candidate SOL-116.

Read the interview with Lipum's CSO Susanne Lindquist at biostock.se:

https://www.biostock.se/en/2023/02/lipums-journey-told-by-cso-and-co-founder/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/